Inhibikase Therapeutics (NASDAQ:IKT) Stock Rating Upgraded by LADENBURG THALM/SH SH

Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by stock analysts at LADENBURG THALM/SH SH to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

A number of other equities research analysts also recently weighed in on IKT. Cantor Fitzgerald upgraded Inhibikase Therapeutics to a “strong-buy” rating in a research report on Thursday, December 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research report on Thursday, January 22nd. Lifesci Capital upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a research report on Monday, February 23rd. Zacks Research upgraded shares of Inhibikase Therapeutics to a “hold” rating in a research report on Tuesday, December 2nd. Finally, HC Wainwright upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a research report on Friday, December 26th. Four analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Inhibikase Therapeutics presently has a consensus rating of “Buy”.

Inhibikase Therapeutics Price Performance

Shares of IKT stock opened at $1.89 on Wednesday. The firm has a market capitalization of $142.09 million, a price-to-earnings ratio of -4.85 and a beta of 0.76. The business’s 50 day moving average is $1.78. Inhibikase Therapeutics has a 1 year low of $1.33 and a 1 year high of $2.58.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.